Trade Zentalis Pharmaceuticals - ZNTL CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Spread | 0.15 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Zentalis Pharmaceuticals Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 15.12 |
Open* | 15.23 |
1-Year Change* | -13.42% |
Day's Range* | 15.12 - 16.01 |
52 wk Range | 9.56-31.46 |
Average Volume (10 days) | 713.66K |
Average Volume (3 months) | 22.85M |
Market Cap | 917.12M |
P/E Ratio | -100.00K |
Shares Outstanding | 70.77M |
Revenue | N/A |
EPS | -4.65 |
Dividend (Yield %) | N/A |
Beta | 1.67 |
Next Earnings Date | Feb 28, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 27, 2024 | 15.12 | 1.03 | 7.31% | 14.09 | 15.15 | 13.83 |
Mar 26, 2024 | 14.03 | 0.83 | 6.29% | 13.20 | 14.29 | 13.20 |
Mar 25, 2024 | 13.51 | -0.01 | -0.07% | 13.52 | 13.95 | 13.23 |
Mar 22, 2024 | 13.55 | -0.03 | -0.22% | 13.58 | 13.78 | 13.31 |
Mar 21, 2024 | 13.59 | 0.34 | 2.57% | 13.25 | 14.13 | 13.24 |
Mar 20, 2024 | 13.61 | -0.07 | -0.51% | 13.68 | 13.78 | 13.05 |
Mar 19, 2024 | 13.82 | 0.21 | 1.54% | 13.61 | 14.08 | 13.52 |
Mar 18, 2024 | 13.79 | 0.16 | 1.17% | 13.63 | 14.17 | 13.58 |
Mar 15, 2024 | 14.25 | 0.47 | 3.41% | 13.78 | 14.64 | 13.60 |
Mar 14, 2024 | 13.99 | -0.95 | -6.36% | 14.94 | 15.25 | 13.70 |
Mar 13, 2024 | 15.17 | 0.74 | 5.13% | 14.43 | 15.31 | 14.36 |
Mar 12, 2024 | 14.73 | 0.99 | 7.21% | 13.74 | 14.96 | 13.31 |
Mar 11, 2024 | 13.75 | -1.34 | -8.88% | 15.09 | 15.69 | 13.31 |
Mar 8, 2024 | 15.34 | 0.55 | 3.72% | 14.79 | 15.69 | 14.76 |
Mar 7, 2024 | 14.79 | 0.27 | 1.86% | 14.52 | 15.06 | 14.22 |
Mar 6, 2024 | 14.50 | 0.53 | 3.79% | 13.97 | 14.54 | 13.92 |
Mar 5, 2024 | 14.17 | 0.01 | 0.07% | 14.16 | 14.52 | 13.96 |
Mar 4, 2024 | 14.47 | -0.57 | -3.79% | 15.04 | 15.10 | 14.18 |
Mar 1, 2024 | 15.20 | 0.40 | 2.70% | 14.80 | 16.10 | 14.40 |
Feb 29, 2024 | 14.85 | -0.67 | -4.32% | 15.52 | 16.06 | 14.69 |
Zentalis Pharmaceuticals Events
Time (UTC) | Country | Event |
---|---|---|
Wednesday, May 8, 2024 | ||
Time (UTC) 12:30 | Country US
| Event Q1 2024 Zentalis Pharmaceuticals Inc Earnings Release Q1 2024 Zentalis Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
Friday, June 14, 2024 | ||
Time (UTC) 13:30 | Country US
| Event Zentalis Pharmaceuticals Inc Annual Shareholders Meeting Zentalis Pharmaceuticals Inc Annual Shareholders MeetingForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0.014 |
Revenue | 0 | 0.014 | |||
Total Operating Expense | 227.287 | 164.96 | 118.787 | 46.845 | 23.797 |
Selling/General/Admin. Expenses, Total | 54.553 | 40.941 | 33.886 | 8.459 | 4.876 |
Research & Development | 172.734 | 166.801 | 84.901 | 38.386 | 18.921 |
Operating Income | -227.287 | -164.96 | -118.787 | -46.845 | -23.783 |
Interest Income (Expense), Net Non-Operating | 5.987 | 0.401 | 0.683 | 0.498 | 0.355 |
Other, Net | -0.016 | 0 | |||
Net Income Before Taxes | -221.3 | -164.559 | -118.104 | -46.363 | -23.428 |
Net Income After Taxes | -220.831 | -164.262 | -118.548 | -46.378 | -23.432 |
Minority Interest | 0.307 | 7.368 | 0.707 | 0.715 | 2.365 |
Net Income Before Extra. Items | -236.806 | -158.725 | -117.841 | -45.663 | -21.067 |
Net Income | -236.806 | -158.725 | -117.841 | -45.663 | -21.067 |
Income Available to Common Excl. Extra. Items | -236.806 | -158.725 | -117.841 | -45.663 | -21.067 |
Income Available to Common Incl. Extra. Items | -236.806 | -158.725 | -117.841 | -45.663 | -21.067 |
Diluted Net Income | -236.806 | -158.725 | -117.841 | -45.663 | -21.067 |
Diluted Weighted Average Shares | 52.857 | 42.688 | 28.113 | 34.5015 | 34.5015 |
Diluted EPS Excluding Extraordinary Items | -4.48013 | -3.71826 | -4.19169 | -1.32351 | -0.61061 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
Diluted Normalized EPS | -4.48013 | -4.29754 | -4.19169 | -1.32351 | -0.61061 |
Unusual Expense (Income) | 0 | -42.782 | |||
Equity In Affiliates | -16.282 | -1.831 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 103.916 | 64.953 | 51.754 | 54.193 | 63.461 |
Selling/General/Admin. Expenses, Total | 15.664 | 11.369 | 11.138 | 12.012 | 19.636 |
Research & Development | 88.252 | 48.584 | 40.616 | 42.181 | 43.825 |
Operating Income | -103.916 | -64.953 | -51.754 | -54.193 | -63.461 |
Interest Income (Expense), Net Non-Operating | 4.451 | 4.109 | 3.232 | 1.905 | 0.424 |
Other, Net | |||||
Net Income Before Taxes | -99.465 | -60.844 | -48.522 | -52.288 | -63.037 |
Net Income After Taxes | -98.86 | -60.952 | -48.162 | -52.129 | -63.054 |
Minority Interest | 0.037 | 0.043 | 0.013 | 0.099 | 0.035 |
Net Income Before Extra. Items | -112.527 | -63.219 | -54.971 | -54.401 | -68.357 |
Net Income | -112.527 | -63.219 | -54.971 | -54.401 | -68.357 |
Income Available to Common Excl. Extra. Items | -112.527 | -63.219 | -54.971 | -54.401 | -68.357 |
Income Available to Common Incl. Extra. Items | -112.527 | -63.219 | -54.971 | -54.401 | -68.357 |
Diluted Net Income | -112.527 | -63.219 | -54.971 | -54.401 | -68.357 |
Diluted Weighted Average Shares | 60.79 | 59.277 | 58.134 | 56.807 | 51.117 |
Diluted EPS Excluding Extraordinary Items | -1.85108 | -1.0665 | -0.94559 | -0.95765 | -1.33727 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -1.85108 | -1.01167 | -0.94559 | -0.95765 | -1.33727 |
Unusual Expense (Income) | 0 | 5 | 0 | 0 | |
Equity In Affiliates | -13.704 | -2.31 | -6.822 | -2.371 | -5.338 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 451.933 | 350.77 | 345.104 | 68.891 | 26.677 |
Cash and Short Term Investments | 437.371 | 339.887 | 338.505 | 67.246 | 25.154 |
Cash & Equivalents | 43.069 | 59.714 | 54.951 | 67.246 | 25.154 |
Total Receivables, Net | 6.382 | 0.004 | 0.417 | 0.14 | 0.917 |
Accounts Receivable - Trade, Net | 0.004 | 0.417 | 0.14 | 0.917 | |
Prepaid Expenses | 7.521 | 10.636 | 6.182 | 1.505 | 0.606 |
Total Assets | 539.31 | 454.507 | 365.555 | 87.481 | 40.998 |
Property/Plant/Equipment, Total - Net | 50.078 | 52.839 | 3.619 | 2.836 | 0.26 |
Property/Plant/Equipment, Total - Gross | 52.138 | 53.631 | 3.869 | 3.003 | 0.316 |
Accumulated Depreciation, Total | -2.06 | -0.792 | -0.25 | -0.167 | -0.056 |
Goodwill, Net | 3.736 | 3.736 | 3.736 | 3.736 | 3.736 |
Intangibles, Net | 0 | 8.8 | 8.8 | 8.8 | |
Other Long Term Assets, Total | 12.35 | 9.667 | 4.296 | 3.218 | 1.525 |
Total Current Liabilities | 56.647 | 43.944 | 28.601 | 14.897 | 6.208 |
Accounts Payable | 11.247 | 11.59 | 8.661 | 4.289 | 3.431 |
Accrued Expenses | 45.016 | 31.383 | 19.53 | 10.608 | 2.554 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.384 | 0.971 | 0.41 | 0 | 0.223 |
Total Liabilities | 105.507 | 90.553 | 56.973 | 25.881 | 16.228 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Deferred Income Tax | 0.853 | 1.622 | 2.48 | 2.463 | 2.463 |
Minority Interest | 0.221 | 0.528 | 24.795 | 6.821 | 7.536 |
Other Liabilities, Total | 47.786 | 44.459 | 1.097 | 1.7 | 0.021 |
Total Equity | 433.803 | 363.954 | 308.582 | 61.6 | 24.77 |
Redeemable Preferred Stock | 0 | 0 | 0 | 141.706 | 59.83 |
Common Stock | 0.059 | 0.045 | 0.041 | 2.887 | 2.27 |
Retained Earnings (Accumulated Deficit) | -596.365 | -359.559 | -200.834 | -82.993 | -37.33 |
Total Liabilities & Shareholders’ Equity | 539.31 | 454.507 | 365.555 | 87.481 | 40.998 |
Total Common Shares Outstanding | 59.2803 | 45.4908 | 41.0403 | 34.5015 | 34.5015 |
Short Term Investments | 394.302 | 280.173 | 283.554 | ||
Additional Paid-In Capital | 1031.46 | 723.593 | 509.339 | ||
Unrealized Gain (Loss) | -1.353 | -0.125 | 0.036 | ||
Other Current Assets, Total | 0.659 | 0.243 | |||
Long Term Investments | 21.213 | 37.495 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 563.929 | 410.226 | 451.933 | 433.89 | |
Cash and Short Term Investments | 552.986 | 392.519 | 437.371 | 421.726 | |
Cash & Equivalents | 266.558 | 36.28 | 43.069 | 42.551 | |
Short Term Investments | 286.428 | 356.239 | 394.302 | 379.175 | |
Total Receivables, Net | 1.81 | 8.293 | |||
Accounts Receivable - Trade, Net | |||||
Prepaid Expenses | 8.222 | 8.474 | 14.562 | 12.164 | |
Total Assets | 621.444 | 489.342 | 539.31 | 529.193 | |
Property/Plant/Equipment, Total - Net | 43.234 | 44.355 | 50.078 | 50.673 | |
Property/Plant/Equipment, Total - Gross | 45.998 | 47.448 | 52.138 | 52.374 | |
Accumulated Depreciation, Total | -2.764 | -3.093 | -2.06 | -1.701 | |
Goodwill, Net | 3.736 | 3.736 | 3.736 | 3.736 | |
Intangibles, Net | |||||
Other Long Term Assets, Total | 10.545 | 12.122 | 12.35 | 12.859 | |
Total Current Liabilities | 51.759 | 56.358 | 56.647 | 54.061 | |
Accounts Payable | 12.305 | 12.818 | 11.247 | 9.82 | |
Accrued Expenses | 38.832 | 43.115 | 45.016 | 43.893 | |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | |
Other Current Liabilities, Total | 0.622 | 0.425 | 0.384 | 0.348 | |
Total Liabilities | 98.303 | 103.855 | 105.507 | 100.689 | |
Total Long Term Debt | 0 | 0 | 0 | 0 | |
Deferred Income Tax | 0 | 0.756 | 0.853 | 1.225 | |
Minority Interest | 0.141 | 0.178 | 0.221 | 0.234 | |
Other Liabilities, Total | 46.403 | 46.563 | 47.786 | 45.169 | |
Total Equity | 523.141 | 385.487 | 433.803 | 428.504 | |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | |
Common Stock | 0.07 | 0.059 | 0.059 | 0.057 | |
Additional Paid-In Capital | 1295.52 | 1045.57 | 1031.46 | 972.111 | |
Retained Earnings (Accumulated Deficit) | -772.111 | -659.584 | -596.365 | -541.394 | |
Other Equity, Total | -0.338 | ||||
Total Liabilities & Shareholders’ Equity | 621.444 | 489.342 | 539.31 | 529.193 | |
Total Common Shares Outstanding | 70.6037 | 59.4423 | 59.2803 | 57.0023 | |
Other Current Assets, Total | 0.911 | 0.94 | 0 | 0 | |
Long Term Investments | 0 | 18.903 | 21.213 | 28.035 | |
Unrealized Gain (Loss) | -0.556 | -1.353 | -2.27 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -237.113 | -166.093 | -118.548 | -46.378 | -23.432 |
Cash From Operating Activities | -163.751 | -154.093 | -86.825 | -39.143 | -24.251 |
Cash From Operating Activities | 1.426 | 0.544 | 0.16 | 0.111 | 0.051 |
Non-Cash Items | 59.453 | -5.101 | 23.702 | 0.617 | 0.308 |
Cash Taxes Paid | 0.012 | 0.02 | 0.018 | 0.015 | 0.004 |
Changes in Working Capital | 13.252 | 16.557 | 7.844 | 6.507 | -1.178 |
Cash From Investing Activities | -114.18 | -18.115 | -284.832 | -0.352 | -0.227 |
Capital Expenditures | -2.548 | -6.107 | -0.758 | -0.352 | -0.227 |
Cash From Financing Activities | 261.043 | 178.521 | 360.439 | 81.83 | 9.472 |
Financing Cash Flow Items | 0 | -1.146 | 18.424 | -0.046 | 0 |
Issuance (Retirement) of Stock, Net | 261.043 | 179.667 | 342.015 | 81.876 | 9.472 |
Net Change in Cash | -16.888 | 6.313 | -11.218 | 42.335 | -15.006 |
Deferred Taxes | -0.769 | 0 | 0.017 | ||
Other Investing Cash Flow Items, Total | -111.632 | -12.008 | -284.074 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -63.262 | -237.113 | -182.129 | -127.629 | -59.237 |
Cash From Operating Activities | -49.283 | -163.751 | -126.422 | -93.223 | -50.196 |
Cash From Operating Activities | 0.36 | 1.426 | 1.067 | 0.692 | 0.344 |
Non-Cash Items | 17.735 | 59.453 | 45.371 | 34.074 | 12.044 |
Changes in Working Capital | -4.019 | 13.252 | 9.269 | -0.36 | -3.347 |
Cash From Investing Activities | 42.121 | -114.18 | -102.286 | -122.304 | 19.796 |
Capital Expenditures | -2.548 | -2.388 | -0.728 | -0.45 | |
Other Investing Cash Flow Items, Total | 42.121 | -111.632 | -99.898 | -121.576 | 20.246 |
Cash From Financing Activities | 0.373 | 261.043 | 211.302 | 210.713 | 1.258 |
Financing Cash Flow Items | 0 | 0 | |||
Issuance (Retirement) of Stock, Net | 0.373 | 261.043 | 211.302 | 210.713 | 1.258 |
Net Change in Cash | -6.789 | -16.888 | -17.406 | -4.814 | -29.142 |
Deferred Taxes | -0.097 | -0.769 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Zentalis Pharmaceuticals Company profile
About Zentalis Pharmaceuticals Inc
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It is developing a pipeline of product candidates with a focus on validated oncology targets. Its lead product candidates, ZN-c5, is an oral selective estrogen receptor degrader. ZN-c5 is in a Phase I/II clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase. ZN-c3 is in a Phase I/II clinical trial for the treatment of advanced solid tumors. Its other products include ZN-d5, a selective inhibitor of B-cell lymphoma 2, in development for the treatment of non-Hodgkin’s lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, in a Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Zentalis Pharmaceuticals Inc revenues was not reported. Net loss increased 35% to $158.7M. Higher net loss reflects Research & Development Expense - Balanci increase of 88% to $145.9M (expense), Stock-based Compensation in R&D increase from $7.3M to $20.9M (expense), Selling, General & Administrative Expens increase of 31% to $23.7M (expense).
Industry: | Bio Therapeutic Drugs |
1359 Broadway, Suite 801
NEW YORK
NEW YORK 10018
US
Income Statement
- Annual
- Quarterly
News
A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024Higher CPI leaves traders unfazed as US equities continue to build momentum
The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.
12:42, 15 March 2024Four reasons why Bitcoin is surging to record highs
Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.
10:18, 14 March 2024China’s National People’s Congress: The markets have again been left wanting more
China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.
08:23, 8 March 2024Central Banks: which one will cut first?
Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut
13:14, 6 March 2024Nvidia (NVDA) confronts high expectations for Q4 results
Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.
12:13, 20 February 2024People also watch
Still looking for a broker you can trust?
Join the 580.000+ traders worldwide that chose to trade with Capital.com